Skip to content

Abbott IMX PSA

by Abbott Laboratories PMA

Active United States

PMA P910007

Overview

This device is a Total, Prostate Specific Antigen (Noncomplexed & Complexed) Immunoassay System for the detection of prostate cancer. It quantifies both free and bound PSA levels in serum or plasma, aiding in the evaluation of prostate health and the monitoring of prostate cancer progression or recurrence.

The Abbott IMX PSA is intended for use in clinical laboratories and is supplied as a reagent kit for in vitro diagnostic testing. It is a Class III device under FDA regulations, with FDA_PMA authorization (PMA Number: P910007). The system requires proper storage at controlled temperatures and adheres to standard laboratory protocols for immunoassay procedures, ensuring accurate and reliable results for diagnostic purposes.

AI-generated from registry data, 18 Sep 2026.Not verified by deviCERTS or the manufacturer

Regulatory status

as of 26 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesFDA PMAAPPR Approved NumberP910007 Date25 Sep 1991ApprovedStatusActive

Coverage

1 jurisdiction

United States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of AmericaUnited States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not known
  • Not covered

United States — FDA PMA Active

Recalls: none on record (FDA, checked 6 Oct 2026)

Specification

PMA

Full name
Abbott Imx(R) Psa*
Trade Name
Axsym Total Psa & Architect Total Psa
Generic Name
Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer
PMA Number
FDA Product Code
MTF
Device Class
Class III
Advisory Committee
Immunology
FDA Decision
APPR Approved

Other devices from Abbott Laboratories

See all devices from Abbott Laboratories →

Questions

  • What clinical purpose does the Abbott IMX PSA system serve in prostate health evaluation?

    The Abbott IMX PSA system quantifies both free and bound (complexed) prostate-specific antigen (PSA) levels in serum or plasma. This helps clinicians evaluate prostate health, assess the risk of prostate cancer, and monitor progression or recurrence of the disease by providing total PSA measurements.

  • Is the Abbott IMX PSA system designed for single-use or repeated testing in a lab setting?

    The device is supplied as a reagent kit intended for use in clinical laboratories, meaning it is designed for repeated testing within a controlled lab environment. Each kit contains materials for multiple assays, but individual components may be single-use depending on the specific protocol.

  • What storage conditions are required for the Abbott IMX PSA reagent kit?

    The Abbott IMX PSA system requires proper storage at controlled temperatures to maintain accuracy and reliability. While exact temperature ranges are not specified, standard laboratory protocols for immunoassay reagents should be followed, typically involving refrigeration or room-temperature storage as per manufacturer guidelines.

  • How does the regulatory pathway for this device differ from other immunoassay systems?

    This device is classified as a Class III medical device under FDA regulations, requiring a Premarket Approval (PMA) application due to its role in diagnosing prostate cancer—a high-risk condition. The PMA pathway ensures rigorous review of safety and effectiveness before market authorization, unlike less stringent pathways for lower-risk devices.